@article{BeckBittlKolleretal.1999, author = {Beck, Eberhard and Bittl, A. and Koller, S. and Merkle, E. and Katalinic, A. and J{\"a}ger, W. and Lang, N.}, title = {Erfassung der fetalen Retardierung mittels Ponderal Index und Gewichtsperzentilen Assessment of Fetal Retardation via Ponderal Index and Weight Percentiles}, series = {In: Geburtsh Frauenheilk 59(1999)2, 62-69}, journal = {In: Geburtsh Frauenheilk 59(1999)2, 62-69}, pages = {62 -- 69}, year = {1999}, abstract = {Zusammenfassung Intrauterin wachstumsretardierte Neugeborene konnten ihr genetisches Wachstumspotential aufgrund einer intrauterinen Mangelversorgung nicht realisieren und werden deshalb zu klein oder zu leicht geboren. Das Merkmal „zu leicht" wird mit Hilfe von Gewichtsperzentilen quantifiziert. Kinder mit einem Gewicht< 10. Perzentile werden als „small for gestational age" (SGA) bezeichnet. Diese Einteilung ber{\"u}cksichtigt jedoch nicht die Proportionen eines Neugeborenen, so daß vor allem asymmetrisch retardierte Neugeborene, deren Gewicht zwar die 10. Perzentile noch {\"u}berschreitet, die jedoch f{\"u}r ihre K{\"o}rpergr{\"o}ße untergewichtig sind, nicht erfaßt werden. Der Ponderal Index (PI) dagegen ber{\"u}cksichtigt sowohl Gewicht als auch L{\"a}nge des Neugeborenen. Kinder mit einem PI < 10. Perzentile werden als „low Ponderal Index" (LPI) klassifiziert. Aus p{\"a}diatrischen Studien ist bekannt, daß LPI-Kinder vermehrt durch Hypoglyk{\"a}mien, Hypothermien, Hypokalz{\"a}mien und Mekoniumaspirationen/Aspirationspneumonien gef{\"a}hrdet sind. Langzeiterhebungen zeigten eine verz{\"o}gerte k{\"o}rperliche Entwicklung und geh{\"a}uft motorische oder neurologische Verhaltensauff{\"a}lligkeiten sowie schulische Probleme. Fragestellung: Ziel der vorliegenden Arbeit war die Frage, ob Mangelgeborene, insbesondere LPI-Neugeborene, auch intrapartum einer erh{\"o}hten Gef{\"a}hrdung ausgesetzt sind. Methoden: Hierzu wurden 3687 Neugeborene retrospektiv erfaßt, die anhand von Perzentilenkurven des betrachteten Kollektivs als SGA, LPI, SGA/LPI oder Vergleichskollektiv klassifiziert wurden. Ergebnisse: Unterschiede im Geburtsmodus zwischen SGA- bzw. LPI-Mangelgeborenen und eutrophen Neugeborenen waren schwach ausgepr{\"a}gt. Demgegen{\"u}ber unterschied sich die Indikation, aufgrund deren ein geburtshilflicher Eingriff vorgenommen werden mußte deutlich. Bei 31 \% aller operativ entbundenen LPI-Neugeborenen, 47 \% der SGA-Neugeborenen und 52 \% der SGA/LPI-Kinder erfolgte die operative Entbindung aus fetaler Indikation, im Vergleich zu 16 \% des Normalkollektivs. Bez{\"u}glich des „fetal outcome", das die Merkmale neonataler S{\"a}ure-Basen-Status, Apgar-Wert, Verlegung in die Kinderklinik und perinatale Mortalit{\"a}t einbezog, verhielten sich die Gruppen SGA, LPI und SGA/LPI in gleicher Weise schlechter gegen{\"u}ber dem Vergleichskollektiv. Die Unterschiede zwischen proportionierten (SGA) und dysproportionierten (LPI) Mangelgeborenen waren weniger deutlich. Schlußfolgerungen: Es zeigte sich, daß das gegenw{\"a}rtige engmaschige, geburtshilfliche Management mit nahezu permanenter CTG-{\"U}berwachung sub partu Probleme rechtzeitig erkennen und beherrschen ließ. Die Erfassung des niedrigen Ponderal Index war zur Erkennung und Vermeidung subpartaler geburtshilflicher Risikofaktoren nicht entscheidend.}, language = {de} } @article{BeckMoldenhauerMerkleetal.1998, author = {Beck, Eberhard and Moldenhauer, A. and Merkle, E. and Kiesewetter, F. and J{\"a}ger, W. and Wildt, L. and Lang, N.}, title = {CA 125 production an release by ovarian cancer cell lines in vitro}, series = {In: The international journal of biological markers 13(1998), 200 - 206}, journal = {In: The international journal of biological markers 13(1998), 200 - 206}, pages = {200 -- 206}, year = {1998}, language = {en} } @article{FehmBeckValeriusetal.1998, author = {Fehm, T. and Beck, Eberhard and Valerius, T. and Gramatzki, M. and J{\"a}ger, W.}, title = {CA 125 elevations in patients with malignant lymphomas}, series = {In: Tumor Biology 19(1998), 283 - 289}, journal = {In: Tumor Biology 19(1998), 283 - 289}, pages = {283 -- 289}, year = {1998}, language = {en} } @article{BeckWagnerAnselminoetal.1997, author = {Beck, Eberhard and Wagner, Maren and Anselmino, Lisa and Xu, Feng-ji and Bast Jr., Robert C. and J{\"a}ger, Wolfram}, title = {Is OVX1 a suitable marker for endometrial cancer?}, series = {In: Gynecologic Oncology 65(1997) 2, 291-296}, journal = {In: Gynecologic Oncology 65(1997) 2, 291-296}, pages = {291 -- 296}, year = {1997}, abstract = {The single most common cause leading to the diagnosis of endometrial cancer is postmenopausal bleeding. Although most patients with early-stage disease (FIGO stage I and II) can be cured, prognosis worsens considerably with increasing stage. While serum CA 125 levels are elevated only in a significant proportion of patients with advanced disease, recently a new serum marker (OVX1) for the detection of early-stage endometrial cancer was reported. Serum OVX1 levels were measured using an OVX1 radioimmunoassay (RIA) or enzyme immunoassay (EIA) in 192 patients with endometrial cancer. CA 125 levels were measured in 112 patients using the CIS ELSA CA 125 kit. Apparently healthy females had mean serum OVX1 levels measured with the OVX1-EIA of 1.34 ± 0.74 U/ml, while patients with endometriosis had mean OVX1 serum levels of 3.15 ± 2.45 U/ml. The mean OVX1 serum level for endometrial cancer patients was 2.00 ± 1.32 U/ml. These values were 2.76 ± 1.62, 6.10 ± 4.66, and 5.37 ± 3.49, respectively, using the OVX1-RIA assay. Applying a cutoff value of 2.8 U/ml, serum OVX1-EIA levels in endometrial cancer patients were increased in 25 of 127 patients (19.7\%) with stage I disease, 5 of 17 patients with stage II (29.4\%), 5 of 22 patients (22.7\%) with stage III, and 4 of 11 patients (36.4\%) with stage IV disease. Using the OVX1-RIA and a cutoff of 7.2 U/ml, serum levels were increased in 22 of 127 (17.3\%) stage I, 6 of 17 (35.3\%) stage II, 5 of 22 (22.7\%) stage III, and 6 of 11 (54.5\%) stage IV patients. Serum CA 125 levels, determined in a total of 112 patients, were elevated above 35 U/ml in 12 of 79 patients (15.2\%) with stage I, 4 of 12 patients (33.3\%) with stage II, 8 of 13 patients (61.5\%) with stage III, and all of 8 patients (100\%) with stage IV disease. While a good correlation between serum CA 125 levels and the clinical stage of the disease was found, no correlation could be detected for OVX1 and stage.}, language = {en} } @article{JaegerSauerbreiBecketal.1995, author = {J{\"a}ger, W. and Sauerbrei, W. and Beck, Eberhard and Maassen, V. and Stumpfe, M. and Meier, W. and Kuhn, W. and J{\"a}nicke, F.}, title = {Unbound MEDLINE A randomized comparison of triptorelin and tamoxifen as treatment of progressive ovarian cancer}, series = {In: Anticancer Research 15(1995)6B, 2639-2642}, journal = {In: Anticancer Research 15(1995)6B, 2639-2642}, issn = {0250-7005}, pages = {2639 -- 2642}, year = {1995}, language = {en} } @incollection{BeckMoldenhauerKiesewetteretal.1994, author = {Beck, Eberhard and Moldenhauer, A. and Kiesewetter, F. and J{\"a}ger, W. and Woldt, L. and Lang, N.}, title = {Analysis of CA 125 production and release by ovarian cancer cells in vitro}, series = {In: Current tumor diagnosis : applications, clinical relevance, research - trends / 7th Symposium on Tumor Markers, Hamburg 1993 ; Satellite Symposium Cancer of the Lung - State and Trends in Diagnosis and Therapy. Ed. by R. Klapdor. - M{\"u}nchen [u.a.] : Zuckschwerdt, 1994. - ISBN 3-88603-509-3}, booktitle = {In: Current tumor diagnosis : applications, clinical relevance, research - trends / 7th Symposium on Tumor Markers, Hamburg 1993 ; Satellite Symposium Cancer of the Lung - State and Trends in Diagnosis and Therapy. Ed. by R. Klapdor. - M{\"u}nchen [u.a.] : Zuckschwerdt, 1994. - ISBN 3-88603-509-3}, pages = {187 -- 191}, year = {1994}, language = {en} } @article{BeckHofmannBernhardtetal.1994, author = {Beck, Eberhard and Hofmann, M. and Bernhardt, G. and J{\"a}ger, W. and Wildt, L. and Lang, N.}, title = {In vitro activity of immunoconjugates between cisplatin and an anti CA125 monoclonal antibody on ovarian cancer cell lines}, series = {In: Cell Biophysics 24/25(1994)1-3, 163-173}, journal = {In: Cell Biophysics 24/25(1994)1-3, 163-173}, issn = {0163-4992}, pages = {163 -- 173}, year = {1994}, abstract = {Cis-diammine dichloro platinum (II) (CDDP), is a highly potent antineoplastic agent that is used in the treatment of ovarian cancer. However, the clinical use of CDDP is restricted by its severe side effects. In order to reduce these side effects and to enhance its therapeutic efficacy, we developed specific immunoconjugates consisting of the murine monoclonal antibody OC125 and CDDP, using diethylene triamine pentaacetic acid (DTPA) as a linker. The coupling efficiencies of the different preparations synthesized, varied between 1.10±0.42 and 2.65±1.60 mol of CDDP per mol of antibody protein. Despite the chemical modification of the antibody molecule, specific binding activity of the OC125-CDDP conjugates toward the CA125 antigen was maintained as was demonstrated by means of immunohisto-/cytochemical staining of frozen sections of ovarian cancer tissue, amniotic epithelium, and the CA125 positive ovarian cancer cell line NIH:OVCAR 3. The antiproliferative activity of the immunoconjugates was tested against the human ovarian cancer cell lines NIH:OVCAR3 and SKOV 3, applying a kinetic crystal violet microassay. Despite the promising results obtained with the specific immuno-staining of the target cells, no significant antiproliferative activity of our immunoconjugates against the cell lines tested was observed. One possible explanation for the lack of antitumor activity could be the fact that CA125 is released in large amounts by the NIH:OVCAR 3 cells. This may have prevented an efficient immunotargeting of the cancer cells by the formation of soluble immune complexes.}, language = {en} } @article{BeckRussoGliozzoetal.1994, author = {Beck, Eberhard and Russo, Pietro and Gliozzo, Biancamaria and J{\"a}ger, Wolfram and Papa, Vincenzo and Wildt, Ludwig and Pezzino, Vincenzo and Lang, Norbert}, title = {Identification of insulin and insulin-like growth factor I (IGF I) receptors in ovarian cancer}, series = {In: Gynecologic Oncology 53(1994)2, 196-201}, journal = {In: Gynecologic Oncology 53(1994)2, 196-201}, issn = {0090-8258}, pages = {196 -- 201}, year = {1994}, abstract = {Abstract The objective of this study was to test if specific insulin and insulin-like growth factor I (IGF I) receptors are expressed in ovarian cancer tissue. Thirteen tissue specimens from primary ovarian cancers, 1 specimen from a primary peritoneal carcinoma, 10 specimens from metastatic lesions of ovarian carcinomas, and 4 specimens from recurrent ovarian cancers together with 13 normal ovaries were tested for their content of insulin and IGF-I receptors, by the application of specific insulin and IGF-I receptor radioimmunoassays. The insulin receptor (IR) and IGF-I receptor (IGF R) content in the primary tumors varied between 23.8-321.4 and 16.4-554.2 ng/0.1 mg DNA, respectively. Metastatic lesions contained between 12.3 and 226.7 ng IR/0.1 mg DNA and between 7.5 and 459.4 ng IGF R/0.1 mg DNA. In recurrent tumors the receptor concentrations were in the range of 41.5-79.8 and 48.9-160.9 ng/0.1 mg DNA for insulin and IGF-I receptors, respectively. Normal ovarian tissue contained between 12.2 and 150.1 ng IR and between 21.4 and 420.1 ng IGF R per 0.1 mg DNA, respectively. As both insulin and IGF-I receptors are present in ovarian cancer tissue, the effects of insulin and IGF-I as potential growth factors in ovarian cancer should be further investigated. Copyright © 1994 Academic Press. All rights reserved.}, language = {en} } @article{BeckRussoPapaetal.1993, author = {Beck, Eberhard and Russo, P. and Papa, V. and J{\"a}ger, W. and Pezzino, V. and Wildt, L. and Vigneri, R. and Lang, N.}, title = {Nachweis von Insulin-Rezeptoren (IR) in Ovarialkarzinomgewebe}, series = {In: Archives of Gynecology and Obstetrics December 254(1993)Iss. 1-4, 1053-1054}, journal = {In: Archives of Gynecology and Obstetrics December 254(1993)Iss. 1-4, 1053-1054}, issn = {0932-0067}, pages = {1053 -- 1054}, year = {1993}, language = {de} } @incollection{BittlBeckJaegeretal.1993, author = {Bittl, A. and Beck, Eberhard and J{\"a}ger, W. and Wildt, L.}, title = {Untersuchungen zur Amenorrhoe unter adjuvanter CMF-Chemotherapie bei Mammakarzinom-Patientinnen}, series = {In: Zytostatikabedingte Nebenwirkungen : Symposium in Pommersfelden, 3. - 4. Juli 1992; 26 Tabellen / Bd.-Hrsg.: N. Lang; W. J{\"a}ger. - M{\"u}nchen [u.a.] : Zuckschwerdt, 1992. - (Aktuelle Onkologie ; 68). - ISBN: 3-88603-458-5}, booktitle = {In: Zytostatikabedingte Nebenwirkungen : Symposium in Pommersfelden, 3. - 4. Juli 1992; 26 Tabellen / Bd.-Hrsg.: N. Lang; W. J{\"a}ger. - M{\"u}nchen [u.a.] : Zuckschwerdt, 1992. - (Aktuelle Onkologie ; 68). - ISBN: 3-88603-458-5}, pages = {10 -- 14}, year = {1993}, language = {de} } @article{GebauerMuellerFehmetal.2004, author = {Gebauer, Gerhard and Mueller, Natalia and Fehm, Tanja and Berkholz, Alexander and Beck, Eberhard and Jaeger, Wolfram and Licht, Peter}, title = {Expression and regulation of luteinizing hormone/human chorionic gonadotropin receptors in ovarian cancer and its correlation to human chorionic gonadotropin-doxorubicin sensitivity}, series = {In: American Journal of Obstetrics \& Gynecology 190 (2004), Iss. 6, pp. 1621-1628}, journal = {In: American Journal of Obstetrics \& Gynecology 190 (2004), Iss. 6, pp. 1621-1628}, pages = {1621 -- 1624}, year = {2004}, abstract = {Objective Ovarian cancer cell lines and tissues express gonadotropin receptors. Conjugation of cytostatics to ligands of these receptors may increase the specificity of cytotoxic drugs. Study design Toxicity of doxorubicin-human chorionic gonadotropin conjugates was determined in 4 ovarian cancer cell lines. Expression and regulation of luteinizing hormone/human chorionic gonadotropin receptors were analyzed before and after treatment with human chorionic gonadotropin, epidermal growth factor, and 8-bromo-cyclic adenosine monophosphate with a nested reverse transcriptase-polymerase chain reaction approach. Results Toxicity of human chorionic gonadotropin-doxorubicin conjugates was increased compared with unconjugated doxorubicin in OVCAR-3 cells. However, drug conjugates failed to demonstrate increased toxicity in other cell lines, especially after preincubation with human chorionic gonadotropin. All cell lines expressed luteinizing hormone/human chorionic gonadotropin receptors. Receptor expression in OVCAR-3 cells was not effected by human chorionic gonadotropin, endothelial growth factor, or 8-bromo-cyclic adenosine monophosphate treatment. In other cell lines, receptor expression was down-regulated by these agents. Conclusion Cytotoxic activity of doxorubicin was increased specifically by conjugation to human chorionic gonadotropin. However, the regulation of luteinizing hormone/human chorionic gonadotropin receptor expression and other compounds may reduce the drug-uptake of the conjugates.}, language = {en} } @article{GebauerFehmBecketal.2003, author = {Gebauer, Gerhard and Fehm, Tanja and Beck, Eberhard and Berkholz, Alexander and Licht, Peter and J{\"a}ger, Wolfram}, title = {Cytotoxic effect of conjugates of doxorubicin and human chorionic gonadotropin (hCG) in breast cancer cells}, series = {In: Breast Cancer Research and Treatment 77(2003)2, pp. 125-131}, journal = {In: Breast Cancer Research and Treatment 77(2003)2, pp. 125-131}, pages = {125 -- 131}, year = {2003}, abstract = {Cytotoxic activity of drug conjugates of human chorionic gonadotropin (hCG) and doxorubicin alone was investigated compared to doxorubicin in breast cancer cells with and without expression of hCG receptors. Expression of hCG receptor was determined in MCF-7 and MB231 breast cancer cell line using a multiplex nested rt-PCR approach. The entire sequence of mRNA encoding for hCG receptor was detected in MCF-7 but not in MB231 breast cancer cell line. Cytostatic effect of doxorubicin-hCG conjugates was investigated in these cell lines in comparison to unconjugated doxorubicin. The number of viable cells was determined after 24, 48, 72, 96, and 120 h. To exclude non-specific uptake of the carrier hCG from the culture media, a similar experiment was performed with albumin-doxorubicin conjugates. The number of viable cells decreased in a concentration depending manner after doxorubicin and hCG-doxorubicin conjugate treatment. However, the cytotoxic effect of hCG-doxorubicin conjugate was 10-fold increased compared to unconjugated doxorubin in hCG-receptor positive MCF-7 but not in hCG-receptor negative MB231 cells. Albumin-doxorubicin conjugates showed no increased toxicity compared to doxorubicin. We conclude that the cytotoxic effect of hCG-doxorubicin conjugates is mediated specifically via the hCG receptor. By using hCG conjugates, the development of more selective cytostatics can be achieved.}, language = {en} } @article{GebauerFehmMerkleetal.2001, author = {Gebauer, Gerhard and Fehm, Tanja and Merkle, Elisabeth and Beck, Eberhard and Lang, Norbert and J{\"a}ger, Wolfram}, title = {Epithelial Cells in Bone Marrow of Breast Cancer Patients at Time of Primary Surgery: Clinical Outcome During Long-Term Follow-Up}, series = {In: J. Clin. Oncol. 19(2001)16, 3669 - 3674}, journal = {In: J. Clin. Oncol. 19(2001)16, 3669 - 3674}, pages = {3669 -- 3674}, year = {2001}, abstract = {PURPOSE: To evaluate the detection of epithelial cells in bone marrow of breast cancer patients as an indicator of metastatic disease. PATIENTS AND METHODS: Between 1989 and 1994, bone marrow biopsies were performed on 393 breast cancer patients during primary surgery. Specimens were stained immunocytochemically for epithelial cells expressing cytokeratins or the epithelial membrane antigen. The long-term outcomes of these patients were analyzed in this study. RESULTS: In 166 of 393 patients, epithelial cells were found in bone marrow (BM) aspirates. These patients were designated BM+. The rate of tumor recurrence or cancer-related death was significantly higher in BM+ patients than in BM- patients. Multivariate analysis using the Cox regression model revealed BM status as a prognostic parameter independent of tumor size and axillary lymph node status. However, tumor size and axillary lymph node status were clearly superior prognostic parameters. CONCLUSION: Disseminated epithelial cells in BM are associated with poor clinical outcome in breast cancer patients. However, the presence of these cells is not a sufficient parameter to predict growing metastases in the majority of patients, suggesting that epithelial cells in the BM of breast cancer patients at the time of surgery have limited metastatic potential. The role of these cells needs to be further evaluated.}, language = {en} } @article{MerkleAckermannBecketal.2000, author = {Merkle, E. and Ackermann, S. and Beck, Eberhard and J{\"a}ger, W. and Lang, N.}, title = {High-Dose versus Low-Dose Cisplatin Chemotherapy plus Treosulfan in Epithelial Ovarian Carcinoma FIGO II-IV: Results of a Prospective Randomized Trial}, series = {In: Onkologie 23(2000)3, 232-238}, journal = {In: Onkologie 23(2000)3, 232-238}, pages = {232 -- 238}, year = {2000}, abstract = {Summary Background: Combination chemotherapies of platinum compounds with alkylating agents have been the standard treatment for patients with advanced ovarian carcinoma over the last decades. The recent development of taxans has added a group of new promising agents; however, long-term results are not yet available. Platin derivates have proven to be an indispensable part in combination chemotherapies for ovarian carcinoma. The dose intensity of cisplatin is, however, still a matter of debate. We report on the long-term results of a prospective randomized trial comparing two dosages of cisplatin combined with treosulfan in patients with advanced epithelial ovarian cancer. Patients and Methods: Between 1988 and 1995, 125 patients with ovarian cancer (FIGO stage II-IV) were randomized to receive 4 cycles (28-day intervals) of either cisplatin 100 mg/m2 (high dose, HD) or 50 mg/m2 (low dose, LD) in combination with 5 g/m2 treosulfan after primary cytoreductive surgery. Postoperative residual tumor was absent in 39 patients (HD: 16; LD: 23), < 2 cm in 61 patients (HD: 36; LD: 25) and > 2 cm in 25 patients (HD: 13; LD: 12). 65 and 60 patients received HD and LD cisplatin, respectively. Second-look surgery was optional. Results:The overall response rate was 70.0\% (HD: 70.9\%; LD: 68.9\%). Pathological complete response (CR) was seen in 45 patients (37.5\%), clinical CR in 23 patients (19.2\%), partial response (PR) in 16 patients (13.3\%), stable disease (SD) in 2 patients, and progression of disease (PD) in 34 patients (28.3\%). 5 patients were not assessable for response. Overall median survival was 25.6 (HD: 26.9, LD: 25.2) months. The overall disease-free survival for responders was 19.6 and 24.7 months (HD and LD, respectively). HD chemotherapy did not result in any significant survival benefit in completely resected patients: HD: 39.8 months versus LD: 49.5 months. In suboptimally debulked patients (residual tumor < 2 cm), median survival was 24.1 months (HD) versus 22.6 months (LD). In patients with residual tumors > 2 cm median survival was 14.6 months (HD) versus 15.5 months (LD). Significantly less side effects were seen in the LD group: anemia (p = 0.008); nephrotoxicity (p = 0.014); alopecia (p = 0.017). Conclusions: Our data suggest that LD cisplatin-based chemotherapy is as effective as HD chemotherapy in patients with advanced epithelial ovarian cancer, but is far less toxic. Copyright © 2000 S. Karger GmbH, Freiburg}, language = {en} } @incollection{BeckSciaccaPandinietal.2001, author = {Beck, Eberhard and Sciacca, Laura and Pandini, Giuseppe and Jaeger, Wolfram and Pezzino, Vincenzo}, title = {Measurement of IGF-1 Receptor Content in Tissues and Cell Lines by Radioimmunoassay (RIA) and ELISA Techniques}, series = {In: Ovarian Cancer : Methods and Protocols / ed. by John M. S. Bartlett. - Totowa, NJ : Humana Press, 2001. - Totowa, NJ : Humana Press, 2001. - (Methods in Molecular Medicine™ ; 39). - ISBN: 978-1-592-59071-1; 978-0-89603-583-6 (ISBN der Printausgabe)}, booktitle = {In: Ovarian Cancer : Methods and Protocols / ed. by John M. S. Bartlett. - Totowa, NJ : Humana Press, 2001. - Totowa, NJ : Humana Press, 2001. - (Methods in Molecular Medicine™ ; 39). - ISBN: 978-1-592-59071-1; 978-0-89603-583-6 (ISBN der Printausgabe)}, pages = {485 -- 492}, year = {2001}, abstract = {The IGF-1 receptor (IGF-1-R) belongs to the tyrosine kinase growth factor receptor family. It is structurally similar to, but distinct from, the insulin receptor, with which it shares a 70\% homology. As expected, it crossreacts with insulin and, vice versa, insulin receptor crossreacts with IGF-1. Numerous studies suggest that IGF-1-R is very important for mitogenesis and is essential for phenotype transformation, at least in rodents (1). In particular, the IGF-1-R has been described in human breast cancer (2-4) and ovarian cancer (5) tissues and in cultured human breast cancer cell lines (6,7).}, language = {en} } @article{BeckVincentiLichtetal.2000, author = {Beck, Eberhard and Vincenti, D. and Licht, P. and Berkholz, A. and J{\"a}ger, W. and Lang, N. and Merkle, E.}, title = {In vitro activity of human chorionic gonadotropin (hCG)--doxorubicin conjugates against ovarian cancer cells}, series = {In: Anticancer research 20(2000)5A, pg 3001-6}, journal = {In: Anticancer research 20(2000)5A, pg 3001-6}, pages = {3001 -- 3006}, year = {2000}, abstract = {BACKGROUND Despite radical surgery and the introduction of novel chemotherapeutic agents, the prognosis of ovarian cancer remains poor. Since in the past the potential role of gonadotropins in the induction and progression of ovarian cancer has been discussed, we conjugated doxorubicin to human chorionic gonadotropin (hCG) in order to specifically target ovarian cancer cells. MATERIALS AND METHODS Doxorubicin was conjugated to hCG via glutaraldehyde. 48 hours post seeding, NIH:OVCAR 3 cells were treated with various concentrations of hCG-conjugated and non-conjugated doxorubicin for 2 hours. Cells were cultured for a total of 168 hours. Cell growth was monitored by a crystal violet assay. RESULTS Conjugating doxorubicin to hCG resulted in an average specific uptake of 22 mol doxorubicin per mol protein (range 3.0-43.3 mol). Incubating NIH:OVCAR 3 cells for 2 hours with the conjugate led to a more than 8 fold increase of the IC50 values compared to non-conjugated doxorubicin (0.55 microM versus 4.43 microM). The antiproliferative activity of both conjugated and free doxorubicin was detectable up to 168 hours post treatment. CONCLUSIONS The present experiments clearly demonstrate a more than 8-fold increase in cytotoxicity of the conjugates compared to free doxorubicin. It was also shown that this effect was not restricted to an acute toxic event but that it resulted in a prolonged antiproliferative activity.}, language = {en} } @inproceedings{ClausBeckGmeineretal.1992, author = {Claus, D. and Beck, Eberhard and Gmeiner, H.J. and Puschmann, E. and Brunh{\"o}lzl, C. and J{\"a}ger, W. and Neund{\"o}rfer, B.}, title = {Neurotoxische Nebenwirkungen von Zytostatika}, series = {In: Ophthalmoneurologie, Therapiekontrolle, Pr{\"a}vention : 65. Jahrestagung vom 23. - 26. September 1992 in Saarbr{\"u}cken/ hrsg. von K. Schimrigk ... Unter Mitwirkung von M. Grundmann ... - Berlin, 1992. - (Verhandlungen der Deutschen Gesellschaft f{\"u}r Neurologie ; 7) (Tagung / Deutsche Gesellschaft f{\"u}r Neurologie ; 65). - ISBN: 3-924171-14-9}, booktitle = {In: Ophthalmoneurologie, Therapiekontrolle, Pr{\"a}vention : 65. Jahrestagung vom 23. - 26. September 1992 in Saarbr{\"u}cken/ hrsg. von K. Schimrigk ... Unter Mitwirkung von M. Grundmann ... - Berlin, 1992. - (Verhandlungen der Deutschen Gesellschaft f{\"u}r Neurologie ; 7) (Tagung / Deutsche Gesellschaft f{\"u}r Neurologie ; 65). - ISBN: 3-924171-14-9}, pages = {738 -- 740}, year = {1992}, language = {de} } @inproceedings{BeckHofmannKiesewetteretal.1992, author = {Beck, Eberhard and Hofmann, M. and Kiesewetter, F. and J{\"a}ger, W. and Wildt, L. and Lang, N.}, title = {Analysis of CA 125 release by ovarian cancer cells in vitro}, series = {In: Tumor associated antigens, oncogenes, receptors, cytokines in tumor diagnosis and therapy at the beginning of the nineties / 6th Symposium on Tumor Markers, Hamburg, [December 9. - 11. 1991] ; Satellite Symposium Cancer of the Breast - State and Trends in Diagnosis and Therapy. Ed. by R. - M{\"u}nchen [u.a.] : Zuckschwerdt, 1992. - ISBN 3-88603-444-5}, booktitle = {In: Tumor associated antigens, oncogenes, receptors, cytokines in tumor diagnosis and therapy at the beginning of the nineties / 6th Symposium on Tumor Markers, Hamburg, [December 9. - 11. 1991] ; Satellite Symposium Cancer of the Breast - State and Trends in Diagnosis and Therapy. Ed. by R. - M{\"u}nchen [u.a.] : Zuckschwerdt, 1992. - ISBN 3-88603-444-5}, pages = {117 -- 121}, year = {1992}, language = {en} } @inproceedings{BeckSeidingerSchneideretal.1992, author = {Beck, Eberhard and Seidinger, M. and Schneider, G. A. and Schuster, M. and Berg, A. and J{\"a}ger, W. and Wildt, L. and Lang, N.}, title = {Toxische Sch{\"a}digungen des Geh{\"o}rs unter Cisplatinhaltiger Chemotherapie bei Patientinnen mit gyn{\"a}kologischen Tumoren}, series = {In: Zytostatikabedingte Nebenwirkungen : Symposium in Pommersfelden, 3. - 4. Juli 1992 ; 26 Tabellen / Bd-Hrsg.: N. Lang ... - M{\"u}nchen [u.a.] : Zuckschwerdt, 1993. - Aktuelle Onkologie ; 8). - ISBN: 3-88603-458-5}, booktitle = {In: Zytostatikabedingte Nebenwirkungen : Symposium in Pommersfelden, 3. - 4. Juli 1992 ; 26 Tabellen / Bd-Hrsg.: N. Lang ... - M{\"u}nchen [u.a.] : Zuckschwerdt, 1993. - Aktuelle Onkologie ; 8). - ISBN: 3-88603-458-5}, pages = {5 -- 9}, year = {1992}, language = {de} } @incollection{JaegerLoefflerBecketal.1992, author = {J{\"a}ger, W. and L{\"o}ffler, B. and Beck, Eberhard and Bellmann, O. and Wolf, A. and Mund-Hoym, S. and Sauerbrei, W. and Wildt, L. and Lang, N.}, title = {Retrospective analysis of GnRH analogue administration in patients with advanced ovarian cancer}, series = {In: GnRH analogues and cancer : plus a review of the treatment of uterine leiomyomata; the proceedings of the 2. International Symposium on GnRH Analogues in Cancer and Human Reproduction, Geneva, November 1990 / ed. by B. Lunenfeld. - Carnforth, Lancs. [u.a.] : Parthenon Publ., 1992. - (Advances in the study of GnRH analogues ; 4). - ISBN: 1-85070-328-0}, booktitle = {In: GnRH analogues and cancer : plus a review of the treatment of uterine leiomyomata; the proceedings of the 2. International Symposium on GnRH Analogues in Cancer and Human Reproduction, Geneva, November 1990 / ed. by B. Lunenfeld. - Carnforth, Lancs. [u.a.] : Parthenon Publ., 1992. - (Advances in the study of GnRH analogues ; 4). - ISBN: 1-85070-328-0}, pages = {69 -- 76}, year = {1992}, language = {en} } @misc{Beck2008, author = {Beck, Eberhard}, title = {Die elektronische Gesundheitskarte - alles sicher, wozu da noch {\"A}ngste?}, year = {2008}, language = {de} } @misc{Beck2010, author = {Beck, Eberhard}, title = {Prozessmodellierung im Krankenhaus}, year = {2010}, language = {de} } @inproceedings{AnlaufBeckEnzmannetal.2008, author = {Anlauf, Heidi and Beck, Eberhard and Enzmann, Thomas and Goetz, Christoph F-J. and Helmst{\"a}dter, Hans Georg and Hochscheidt, R{\"u}diger and Kaschel, Martin and Naumann, Michael and Prochnow, Antje C. and Schiefner, Andreas and Schmidt, Gabriele and Skonetzki-Cheng, Stefan and Tiemann, Dietlind and Wikarski, Dietmar}, title = {Elektronische Gesundheitskarte}, publisher = {Alcatel-Lucent-Stiftung}, address = {Stuttgart}, organization = {Hochschulkolleg E-Government}, pages = {57}, year = {2008}, language = {de} } @inproceedings{BeckBoegerBogedalyetal.2010, author = {Beck, Eberhard and B{\"o}ger, Astrid and Bogedaly, Antje and Enzmann, Thomas and Goetz, Christoph F.-J. and v. Harbou, Kai and Oeff, Michael and Schmidt, Gabriele and Schrader, Thomas and Wikarski, Dietmar and Wolf, Ute}, title = {Telemedizin und Kommunikation : Medizinische Versorgung {\"u}ber r{\"a}umliche Distanzen}, publisher = {Alcatel-Lucent Stiftung}, address = {Stuttgart}, pages = {46 S.}, year = {2010}, language = {de} } @inproceedings{SchulzBeck2014, author = {Schulz, C. and Beck, Eberhard}, title = {Evaluation von BPMN als Werkzeug f{\"u}r die standardisierte Dokumentation medizinischer Prozesse am Beispiel des Prostatakarzinoms}, series = {MedPro 2014, Der informierte Mensch in der Medizin - Prozesse, Daten und Entscheidungen ; Tagungsband ; Brandenburg an der Havel, 6. November 2014}, booktitle = {MedPro 2014, Der informierte Mensch in der Medizin - Prozesse, Daten und Entscheidungen ; Tagungsband ; Brandenburg an der Havel, 6. November 2014}, editor = {Beck, Eberhard and Schrader, Thomas and Wikarski, Dietmar}, publisher = {Fachhochschule}, address = {Brandenburg an der Havel}, pages = {63 -- 69}, year = {2014}, language = {de} } @misc{AndrzejewskiLedwonSchraderetal.2012, author = {Andrzejewski, Dennis and Ledwon, P. and Schrader, T. and Beck, Eberhard}, title = {M{\"o}glichkeiten und Grenzen der BPMN als Werkzeug zur Modellierung von medizinischen Prozessen und evidence-basierten Behandlungspfaden}, series = {32. Jahrestagung der Deutschen Gesellschaft f{\"u}r Senologie, 5. - 7. Juli 2012, Stuttgart}, journal = {32. Jahrestagung der Deutschen Gesellschaft f{\"u}r Senologie, 5. - 7. Juli 2012, Stuttgart}, year = {2012}, language = {de} } @misc{AndrzejewskiHaeuslerLedwonetal.2013, author = {Andrzejewski, Dennis and Haeusler, N. and Ledwon, P. and Boersch, Ingo and Beck, Eberhard}, title = {Die Analyse des Entscheidungsprozesses in der Senologie zur Konzeption eines entscheidungsunterst{\"u}tzenden Systems}, year = {2013}, language = {de} } @misc{AndrzejewskiBoerschSchraderetal.2014, author = {Andrzejewski, Dennis and Boersch, Ingo and Schrader, Thomas and Haeusler, N. and Ledwon, P. and Beck, Eberhard}, title = {Potentials of Computer-aided Decision Support Systems in Medicine}, year = {2014}, language = {en} } @misc{BollmannBeck2014, author = {Bollmann, M. and Beck, Eberhard}, title = {Gestaltung und Entwicklung eines Informationsportals zur medizinischen Entscheidungsunterst{\"u}tzung f{\"u}r Brustkrebspatienten}, year = {2014}, language = {de} } @misc{BeckDatheOpeletal.2014, author = {Beck, Eberhard and Dathe, G. and Opel, R. and Theuer, M. and Busse, S. and Sigwarth, T. and Laube, F. and Feustel, T. and Bartow, M. and Ludwig, C. and Liefold, M.}, title = {Patienteninformationen - Informierte Patienten}, year = {2014}, language = {de} } @inproceedings{BollmannAndrzejewskiSchulzetal.2014, author = {Bollmann, M. and Andrzejewski, Dennis and Schulz, C. and Pelchen, C. and Beck, Eberhard and Haeusler, N.}, title = {Konzeption einer prozessgesteuerten Informationsplattform f{\"u}r Patientinnen mit Brustkrebs}, series = {MedPro 2014, Der informierte Mensch in der Medizin - Prozesse, Daten und Entscheidungen ; Tagungsband ; Brandenburg an der Havel, 6. November 2014}, booktitle = {MedPro 2014, Der informierte Mensch in der Medizin - Prozesse, Daten und Entscheidungen ; Tagungsband ; Brandenburg an der Havel, 6. November 2014}, editor = {Beck, Eberhard}, publisher = {Fachhochschule}, address = {Brandenburg an der Havel}, pages = {32 -- 37}, year = {2014}, language = {de} } @inproceedings{AndrzejewskiHaeuslerBeck2014, author = {Andrzejewski, Dennis and Haeusler, N. and Beck, Eberhard}, title = {Die Abbildung von medizinischen Entscheidungsstrukturen am Beispiel des Mammakarzinoms}, series = {MedPro 2014, Der informierte Mensch in der Medizin - Prozesse, Daten und Entscheidungen ; Tagungsband ; Brandenburg an der Havel, 6. November 2014}, booktitle = {MedPro 2014, Der informierte Mensch in der Medizin - Prozesse, Daten und Entscheidungen ; Tagungsband ; Brandenburg an der Havel, 6. November 2014}, editor = {Beck, Eberhard}, publisher = {Fachhochschule}, address = {Brandenburg an der Havel}, pages = {56 -- 62}, year = {2014}, language = {de} } @inproceedings{AndrzejewskiJentschMarkusetal.2015, author = {Andrzejewski, Dennis and Jentsch, P. and Markus, A. M. and Tetzlaff, Laura and Haeusler, N. and Beck, Eberhard}, title = {Entwicklung eines webbasierten Prototyps f{\"u}r die leitliniengerechte Entscheidungsunterst{\"u}tzung beim prim{\"a}ren Mammakarzinom - Wie k{\"o}nnen Therapieempfehlungen und deren Begr{\"u}ndungen optimal dokumentiert werden?}, series = {GMDS 2015. 60. Jahrestagung der Deutschen Gesellschaft f{\"u}r Medizinische Informatik, Biometrie und Epidemiologie e.V. (GMDS). Krefeld, 06.-09.09.2015}, booktitle = {GMDS 2015. 60. Jahrestagung der Deutschen Gesellschaft f{\"u}r Medizinische Informatik, Biometrie und Epidemiologie e.V. (GMDS). Krefeld, 06.-09.09.2015}, publisher = {German Medical Science GMS Publishing House}, address = {D{\"u}sseldorf}, doi = {10.3205/15gmds070}, url = {http://nbn-resolving.de/urn:nbn:de:0183-15gmds0704}, year = {2015}, language = {de} } @inproceedings{BeckLiefoldWagneretal.2015, author = {Beck, Eberhard and Liefold, Marius and Wagner, Dennis and Buss, Sebastian and Knackmuß, Jenny and Fotio, Paty and Hielscher, Nele and Laube, Frederick and Sigwarth, Timo and Truber, Jessica and Pelchen, Lutz and Schmidt, Gabriele and Schrader, Thomas}, title = {Modellierung medizinischer Prozesse als Grundlage f{\"u}r die systematische klinische Risikoanalyse}, series = {MedPro 2015, Medizinische Prozesse - Patienten - Sicherheit : Tagungsband ; Brandenburg an der Havel, 5. November 2015}, booktitle = {MedPro 2015, Medizinische Prozesse - Patienten - Sicherheit : Tagungsband ; Brandenburg an der Havel, 5. November 2015}, publisher = {Fachhochschule}, address = {Brandenburg an der Havel}, pages = {24 -- 37}, year = {2015}, language = {de} } @incollection{AndrzejewskiBreitschwerdtBeck2017, author = {Andrzejewski, Dennis and Breitschwerdt, R{\"u}diger and Beck, Eberhard}, title = {Digitales Entscheidungsmanagement in der Medizin: Modellierung von Behandlungsempfehlungen in der Onkologie}, series = {Digitale Transformation von Dienstleistungen im Gesundheitswesen Teil: 2., Impulse f{\"u}r das Management}, booktitle = {Digitale Transformation von Dienstleistungen im Gesundheitswesen Teil: 2., Impulse f{\"u}r das Management}, publisher = {Springer Gabler}, address = {Wiesbaden}, isbn = {978-3-658-12392-5}, publisher = {Technische Hochschule Brandenburg}, pages = {153 -- 166}, year = {2017}, language = {de} } @inproceedings{HildebrandtAndrzejewskiSchmidtetal.2013, author = {Hildebrandt, Sebastian and Andrzejewski, Dennis and Schmidt, Rumen and Beck, Eberhard}, title = {Entscheidungsunterst{\"u}tzendes System in der Medizin am Beispiel der Dia­gnosen Mammakarzinom und Akutes Abdomen}, series = {14. Nachwuchswissenschaftlerkonferenz Ost- und Mitteldeutscher Fachhochschulen (NWK 14) : Brandenburg an der Havel am 18. April 2013 ; Tagungsband}, booktitle = {14. Nachwuchswissenschaftlerkonferenz Ost- und Mitteldeutscher Fachhochschulen (NWK 14) : Brandenburg an der Havel am 18. April 2013 ; Tagungsband}, editor = {Fischer, Arno}, publisher = {H{\"u}lsbusch}, address = {Gl{\"u}ckstadt}, isbn = {978-3-86488-037-7}, pages = {429 -- 430}, year = {2013}, language = {de} } @inproceedings{AndrzejewskiTetzlaffBecketal.2015, author = {Andrzejewski, Dennis and Tetzlaff, Laura and Beck, Eberhard and Haeusler, Nicole}, title = {The transparent representation of medical decision structures based on the example pf breast cancer treatment}, series = {HEALTHINF 2015 : proceedings of the International Conference on Health Informatics : Lisbon, Portugal, 12 - 15 January 2015 ; [... part of: BIOSTEC 2015, 8th International Joint Conference on Biomedical Engineering Systems and Technologies]}, booktitle = {HEALTHINF 2015 : proceedings of the International Conference on Health Informatics : Lisbon, Portugal, 12 - 15 January 2015 ; [... part of: BIOSTEC 2015, 8th International Joint Conference on Biomedical Engineering Systems and Technologies]}, publisher = {SCITEPRESS}, isbn = {978-989-758-068-0}, doi = {10.5220/0005283306170621}, pages = {617 -- 621}, year = {2015}, language = {en} } @inproceedings{AndrzejewskiJentschMarkusetal.2015, author = {Andrzejewski, Dennis and Jentsch, P. and Markus, A. M. and Tetzlaff, Laura and Haeusler, N. and Beck, Eberhard}, title = {Therapeutische Entscheidungen beim Mammakarzinom - Wie k{\"o}nnen leitliniengerechte und nicht-leitliniengerechte Entscheidungen am besten dokumentiert werden?}, series = {35. Jahrestagung der Deutschen Gesellschaft f{\"u}r Senologie, Leipzig 2015}, booktitle = {35. Jahrestagung der Deutschen Gesellschaft f{\"u}r Senologie, Leipzig 2015}, year = {2015}, language = {de} } @article{DueckBeckSteckelberg2022, author = {D{\"u}ck, M. and Beck, Eberhard and Steckelberg, A.}, title = {Literaturrecherche zur Leitliniengetreue Behandlung von Brustkrebspatientinnen}, series = {Geburtshilfe und Frauenheilkunde}, volume = {82}, journal = {Geburtshilfe und Frauenheilkunde}, number = {6}, publisher = {Thieme}, doi = {10.1055/s-0042-1749035}, pages = {631}, year = {2022}, language = {de} } @inproceedings{AndrzejewskiBollmannSchulzetal.2015, author = {Andrzejewski, Dennis and Bollmann, M. and Schulz, C. and Markus, A. and Jentsch, P. and H{\"a}usler, N. and Beck, Eberhard}, title = {Konzeption eines am Behandlungsprozess orientierten Informationssystems f{\"u}r Brustkrebspatientinnen, deren Angeh{\"o}rige und Freunde}, series = {212. Tagung der Niederrheinisch-Westf{\"a}lischen Gesellschaft f{\"u}r Gyn{\"a}kologie und Geburtshilfe (NWGGG) K{\"o}ln, 12.-13. Juni 2015}, booktitle = {212. Tagung der Niederrheinisch-Westf{\"a}lischen Gesellschaft f{\"u}r Gyn{\"a}kologie und Geburtshilfe (NWGGG) K{\"o}ln, 12.-13. Juni 2015}, year = {2015}, language = {de} } @inproceedings{AndrzejewskiJentschMarkusetal.2015, author = {Andrzejewski, Dennis and Jentsch, P. and Markus, A. M. and H{\"a}usler, N. and Tetzlaff, Laura and Beck, Eberhard}, title = {Entwicklung eines webbasierten Prototyps f{\"u}r die leitliniengerechte Entscheidungsunterst{\"u}tzung beim prim{\"a}ren Mammakarzinom - Wie k{\"o}nnen Therapieempfehlungen und deren Begr{\"u}ndungen optimal dokumentiert werden?}, series = {Fortschritt durch Forschung : multidisziplin{\"a}re Wissenschaft in der GMDS ; 06. - 09. September 2015 an der Hochschule Niederrhein in Krefeld / GMDS. [Veranst. Deutsche Gesellschaft f{\"u}r Medizinische Informatik, Biometrie und Epidemiologie e.V.]}, booktitle = {Fortschritt durch Forschung : multidisziplin{\"a}re Wissenschaft in der GMDS ; 06. - 09. September 2015 an der Hochschule Niederrhein in Krefeld / GMDS. [Veranst. Deutsche Gesellschaft f{\"u}r Medizinische Informatik, Biometrie und Epidemiologie e.V.]}, year = {2015}, language = {de} } @inproceedings{AndrzejewskiTetzlaffDeBoeretal.2015, author = {Andrzejewski, Dennis and Tetzlaff, Laura and DeBoer, Julien and Beck, Eberhard and Haeusler, Nicole}, title = {The Transparent Representation of Medical Decision Structures Based on the Example of Breast Cancer Treatment}, series = {HEALTHINF 2015 : proceedings of the International Conference on Health Informatics : Lisbon, Portugal, 12 - 15 January 2015 ; [... part of: BIOSTEC 2015, 8th International Joint Conference on Biomedical Engineering Systems and Technologies]}, booktitle = {HEALTHINF 2015 : proceedings of the International Conference on Health Informatics : Lisbon, Portugal, 12 - 15 January 2015 ; [... part of: BIOSTEC 2015, 8th International Joint Conference on Biomedical Engineering Systems and Technologies]}, publisher = {SCITEPRESS}, isbn = {978-989-758-068-0}, pages = {617 -- 621}, year = {2015}, language = {en} } @inproceedings{LiefoldBeck2015, author = {Liefold, Marius and Beck, Eberhard}, title = {Individuelle in vitro DNA-Schadensantwort auf eine Chemotherapie am Beispiel von R-Benda durch die Bestimmung von γ -H2AX-Foci in peripheren Lymphozyte}, series = {16. Nachwuchswissenschaftlerkonferenz (NWK 16) :Tagungsband, Berlin, 16. April 2015}, booktitle = {16. Nachwuchswissenschaftlerkonferenz (NWK 16) :Tagungsband, Berlin, 16. April 2015}, editor = {Knauth, Matthias}, publisher = {Berliner Wissenschafts-Verlag}, address = {Berlin}, organization = {Nachwuchswissenschaftlerkonferenz <16., 2015, Berlin>}, isbn = {978-3-8305-2044-3}, pages = {209 -- 215}, year = {2015}, language = {de} } @inproceedings{AndrzejewskiBeckTetzlaffetal.2015, author = {Andrzejewski, Dennis and Beck, Eberhard and Tetzlaff, Laura and DeBoer, Julien and Haeusler, Nicole}, title = {Die Modellierung von medizinischen Entscheidungen mit BPMN und DMN - Ein Vergleich}, series = {16. Nachwuchswissenschaftlerkonferenz (NWK 16) :Tagungsband, Berlin, 16. April 2015}, booktitle = {16. Nachwuchswissenschaftlerkonferenz (NWK 16) :Tagungsband, Berlin, 16. April 2015}, editor = {Knaut, Matthias}, publisher = {Berliner Wissenschafts-Verlag}, address = {Berlin}, organization = {Nachwuchswissenschaftlerkonferenz <16., 2015, Berlin>}, isbn = {978-3-8305-2044-3}, pages = {376 -- 384}, year = {2015}, language = {de} } @inproceedings{SchroederTetzlaffBecketal.2017, author = {Schr{\"o}der, Cornelia and Tetzlaff, Laura and Beck, Eberhard and L{\"o}we, Katharina and Schrader, Thomas}, title = {Von der Einzelfallbetrachtung zur strukturierten Analyse von CIRS-F{\"a}llen - die Analyse von 52 F{\"a}llen aus dem CIRSmedical}, series = {62. Jahrestagung der Deutschen Gesellschaft f{\"u}r Medizinische Informatik, Biometrie und Epidemiologie e.V. (GMDS) : 17.09. - 21.09.2017, Oldenburg}, booktitle = {62. Jahrestagung der Deutschen Gesellschaft f{\"u}r Medizinische Informatik, Biometrie und Epidemiologie e.V. (GMDS) : 17.09. - 21.09.2017, Oldenburg}, publisher = {German Medical Science GMS Publishing House}, address = {D{\"u}sseldorf}, organization = {Deutsche Gesellschaft f{\"u}r Medizinische Informatik, Biometrie und Epidemiologie}, doi = {doi: 10.3205/17gmds059}, year = {2017}, language = {de} } @inproceedings{BeckSchraderLoewe2016, author = {Beck, Eberhard and Schrader, T. and L{\"o}we, K.}, title = {Patient safety - prospective risk analysis in medical environments}, series = {4th Nordic Conference on Research in Patient Safety and Quality in Healthcare (NSQH2016), 18 May 2016 - 20 Oct 2016, Kuopio, Finland}, booktitle = {4th Nordic Conference on Research in Patient Safety and Quality in Healthcare (NSQH2016), 18 May 2016 - 20 Oct 2016, Kuopio, Finland}, year = {2016}, language = {en} } @inproceedings{AndrzejewskiBreitschwerdtFellmannetal.2016, author = {Andrzejewski, Dennis and Breitschwerdt, R. and Fellmann, R. and Beck, Eberhard}, title = {Entscheidungsmodellierung in der Senologie - K{\"o}nnen Entscheidungen der operativen Therapie transparent in einer Entscheidungsmatrix dargestellt werden?}, series = {36. Jahrestagung der Deutschen Gesellschaft f{\"u}r Senologie, 26. bis 28. Mai 2016, Dresden}, booktitle = {36. Jahrestagung der Deutschen Gesellschaft f{\"u}r Senologie, 26. bis 28. Mai 2016, Dresden}, year = {2016}, language = {de} } @inproceedings{KuenzelSchossauBaseneretal.2016, author = {K{\"u}nzel, Ulrike and Schossau, Thomas and Basener, Jan and Dachner, Matthias and Nejdl, Kristin and Monga Sindeu, Tabea and Beck, Eberhard}, title = {Informationssuche im Internet - Suchverhalten von an Brustkrebs erkrankten und Nicht-Betroffenen}, series = {Gemeinsam informiert entscheiden. 17. Jahrestagung des Deutschen Netzwerks Evidenzbasierte Medizin. K{\"o}ln, 03.-05.03.2016}, booktitle = {Gemeinsam informiert entscheiden. 17. Jahrestagung des Deutschen Netzwerks Evidenzbasierte Medizin. K{\"o}ln, 03.-05.03.2016}, publisher = {German Medical Science GMS Publishing House}, address = {D{\"u}sseldorf}, doi = {10.3205/16ebm117}, year = {2016}, language = {de} } @inproceedings{AndrzejewskiBeckJentschetal.2016, author = {Andrzejewski, Dennis and Beck, Eberhard and Jentsch, Peter and Breitschwerdt, R{\"u}diger}, title = {Prototypical implementation of an expert system supporting medical documentation and clinical decision}, series = {32. Deutscher Krebskongress Krebsmedizin heute: pr{\"a}ventiv, personalisiert, pr{\"a}zise und partizipativ, Berlin, 24.-27. Februar 2016}, booktitle = {32. Deutscher Krebskongress Krebsmedizin heute: pr{\"a}ventiv, personalisiert, pr{\"a}zise und partizipativ, Berlin, 24.-27. Februar 2016}, year = {2016}, language = {en} } @article{AndrzejewskiBreitschwerdtFellmannetal.2017, author = {Andrzejewski, Dennis and Breitschwerdt, R{\"u}diger and Fellmann, Michael and Beck, Eberhard}, title = {Supporting breast cancer decisions using formalized guidelines and experts decision patterns: initial prototype and evaluation}, series = {Health Information Science and Systems}, volume = {5}, journal = {Health Information Science and Systems}, publisher = {Springer International Publishing}, doi = {10.1007/s13755-017-0035-8}, pages = {12}, year = {2017}, language = {en} } @inproceedings{LiefoldDatheBartowetal.2014, author = {Liefold, M. and Dathe, G. and Bartow, M. and Busse, S. and Sigwarth, T. and Laube, F. and Feustel, T. and Ludwig, C. and Opel, R. and Theuer, M. and Beck, Eberhard}, title = {Patienteninformationen - informierte PatientInnen Welche Informationen ben{\"o}tigen Menschen mit Krebserkrankungen?}, series = {Tagungsband / 15. Nachwuchswissenschaftlerkonferenz : [24. April 2014, Magdeburg]}, booktitle = {Tagungsband / 15. Nachwuchswissenschaftlerkonferenz : [24. April 2014, Magdeburg]}, editor = {Mugele, Jan}, publisher = {Meine}, address = {Magdeburg}, isbn = {978-3-941305-45-8}, pages = {180 -- 184}, year = {2014}, language = {de} } @inproceedings{BollmannAndrzejewskiBeck2014, author = {Bollmann, M. and Andrzejewski, Dennis and Beck, Eberhard}, title = {Der Entwurf eines Informationsportals zur Unterst{\"u}tzung von Patienten mit dem Konzept des ,,Shared Decision Making" am Beispiel Brustkrebs}, series = {Tagungsband / 15. Nachwuchswissenschaftlerkonferenz : [24. April 2014, Magdeburg]}, booktitle = {Tagungsband / 15. Nachwuchswissenschaftlerkonferenz : [24. April 2014, Magdeburg]}, editor = {Mugele, Jan}, publisher = {Meine}, address = {Magdeburg}, isbn = {978-3-941305-45-8}, pages = {153 -- 158}, year = {2014}, language = {de} } @inproceedings{VogelBeck2014, author = {Vogel, S. and Beck, Eberhard}, title = {Konzeption einer Diabetes Telemonitoring Software}, series = {Tagungsband / 15. Nachwuchswissenschaftlerkonferenz : [24. April 2014, Magdeburg]}, booktitle = {Tagungsband / 15. Nachwuchswissenschaftlerkonferenz : [24. April 2014, Magdeburg]}, editor = {Mugele, Jan}, publisher = {Meine}, address = {Magdeburg}, isbn = {978-3-941305-45-8}, pages = {318 -- 324}, year = {2014}, language = {de} }